000841974 001__ 841974
000841974 005__ 20210129232130.0
000841974 0247_ $$2doi$$a10.1093/brain/awx356
000841974 0247_ $$2ISSN$$a0006-8950
000841974 0247_ $$2ISSN$$a1460-2156
000841974 0247_ $$2WOS$$aWOS:000426813600032
000841974 0247_ $$2Handle$$a2128/21495
000841974 0247_ $$2altmetric$$aaltmetric:31269974
000841974 0247_ $$2pmid$$apmid:29309600
000841974 037__ $$aFZJ-2018-00261
000841974 041__ $$aEnglish
000841974 082__ $$a610
000841974 1001_ $$00000-0002-3377-5684$$aRichter, Nils$$b0$$eCorresponding author
000841974 245__ $$aEffect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
000841974 260__ $$aOxford$$bOxford Univ. Press$$c2018
000841974 3367_ $$2DRIVER$$aarticle
000841974 3367_ $$2DataCite$$aOutput Types/Journal article
000841974 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521462957_8744
000841974 3367_ $$2BibTeX$$aARTICLE
000841974 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000841974 3367_ $$00$$2EndNote$$aJournal Article
000841974 520__ $$aIn early Alzheimer’s disease, which initially presents with progressive loss of short-term memory, neurodegeneration especially affects cholinergic neurons of the basal forebrain. Pharmacotherapy of Alzheimer’s disease therefore often targets the cholinergic system. In contrast, cholinergic pharmacotherapy of mild cognitive impairment is debated since its efficacy to date remains controversial. We here investigated the relationship between cholinergic treatment effects and the integrity of the cholinergic system in mild cognitive impairment due to Alzheimer’s disease. Fourteen patients with high likelihood of mild cognitive impairment due to Alzheimer’s disease and 16 age-matched cognitively normal adults performed an episodic memory task during functional magnetic resonance imaging under three conditions: (i) without pharmacotherapy; (ii) with placebo; and (iii) with a single dose of rivastigmine (3 mg). Cortical acetylcholinesterase activity was measured using PET with the tracer 11C-N-methyl-4-piperidyl acetate (MP4A). Cortical acetylcholinesterase activity was significantly decreased in patients relative to controls, especially in the lateral temporal lobes. Without pharmacotherapy, mild cognitive impairment was associated with less memory-related neural activation in the fusiform gyrus and impaired deactivation in the posterior cingulate cortex, relative to controls. These differences were attenuated under cholinergic stimulation with rivastigmine: patients showed increased neural activation in the right fusiform gyrus but enhanced deactivation of the posterior cingulate cortex under rivastigmine, compared to placebo. Conversely, controls showed reduced activation of the fusiform gyrus and reduced deactivation of the posterior cingulate under rivastigmine, compared to placebo. In both groups, the change in neural activation in response to rivastigmine was negatively associated with local acetylcholinesterase activity. At the behavioural level, an analysis of covariance revealed a significant group × treatment interaction in episodic memory performance when accounting for hippocampal grey matter atrophy and function. Our results indicate that rivastigmine differentially affects memory-related neural activity in patients with mild cognitive impairment and cognitively normal, age-matched adults, depending on acetylcholinesterase activity as a marker for the integrity of the cortical cholinergic system. Furthermore, hippocampal integrity showed an independent association with the response of memory performance to acetylcholinesterase inhibition.
000841974 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000841974 588__ $$aDataset connected to CrossRef
000841974 7001_ $$0P:(DE-HGF)0$$aBeckers, Nora$$b1
000841974 7001_ $$0P:(DE-Juel1)131736$$aOnur, Özgür$$b2
000841974 7001_ $$0P:(DE-HGF)0$$aDietlein, Markus$$b3
000841974 7001_ $$0P:(DE-HGF)0$$aTittgemeyer, Marc$$b4
000841974 7001_ $$0P:(DE-HGF)0$$aKracht, Lutz$$b5
000841974 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b6
000841974 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b7
000841974 7001_ $$0P:(DE-Juel1)131730$$aKukolja, Juraj$$b8
000841974 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awx356$$n3$$p903–915$$tBrain$$v141$$x1460-2156$$y2018
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/awx356.pdf$$yRestricted
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/awx356.gif?subformat=icon$$xicon$$yRestricted
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/awx356.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/awx356.jpg?subformat=icon-180$$xicon-180$$yRestricted
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/awx356.jpg?subformat=icon-640$$xicon-640$$yRestricted
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/awx356.pdf?subformat=pdfa$$xpdfa$$yRestricted
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/Richter_2018_Post%20Print_BRAIN_Effect%20of%20cholinergic%20treatment%20depends%20on%20cholinergic%20integrity%20in%20early%20Alzheimers%20disease.pdf$$yOpenAccess
000841974 8564_ $$uhttps://juser.fz-juelich.de/record/841974/files/Richter_2018_Post%20Print_BRAIN_Effect%20of%20cholinergic%20treatment%20depends%20on%20cholinergic%20integrity%20in%20early%20Alzheimers%20disease.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000841974 909CO $$ooai:juser.fz-juelich.de:841974$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000841974 9101_ $$0I:(DE-588b)5008462-8$$60000-0002-3377-5684$$aForschungszentrum Jülich$$b0$$kFZJ
000841974 9101_ $$0I:(DE-HGF)0$$60000-0002-3377-5684$$a INM_3$$b0
000841974 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131736$$aForschungszentrum Jülich$$b2$$kFZJ
000841974 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b6$$kFZJ
000841974 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000841974 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131730$$aForschungszentrum Jülich$$b8$$kFZJ
000841974 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000841974 9141_ $$y2018
000841974 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000841974 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000841974 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000841974 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2015
000841974 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBRAIN : 2015
000841974 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000841974 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000841974 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000841974 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000841974 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000841974 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000841974 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000841974 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000841974 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000841974 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000841974 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000841974 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000841974 920__ $$lyes
000841974 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000841974 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x1
000841974 980__ $$ajournal
000841974 980__ $$aVDB
000841974 980__ $$aUNRESTRICTED
000841974 980__ $$aI:(DE-Juel1)INM-3-20090406
000841974 980__ $$aI:(DE-Juel1)INM-5-20090406
000841974 9801_ $$aFullTexts